Arvee Laborat.

Who are the top shareholders of the Arvee Laborat.?

The top shareholders of Arvee Laborat are Shalin Sudhakarbhai Patel, holding 36.68%, and Gitaben Dinehsbhai Patel, with 9.98%. Individual investors collectively own 26.33%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Arvee Laborat include Shalin Sudhakarbhai Patel, who is the promoter with the highest holding at 36.68%. The highest public shareholder is Gitaben Dinehsbhai Patel, holding 9.98%. Additionally, individual investors collectively hold 26.33% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

how big is Arvee Laborat.?

As of Jun 06, Arvee Laboratories (India) Ltd has a market capitalization of 196.00 Cr and reported net sales of 38.49 Cr and net profit of 2.14 Cr over the latest four quarters. Shareholder's funds are 29.11 Cr, with total assets of 38.20 Cr as of Mar'24.

Market Cap: As of Jun 06, Arvee Laboratories (India) Ltd has a market capitalization of 196.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes the periods of Mar'25, Dec'24, Sep'24, and Jun'24, is 38.49 Cr. The sum of Net Profit for the same quarters is 2.14 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 29.11 Cr, while Total Assets amount to 38.20 Cr.

What does Arvee Laborat. do?

Arvee Laboratories (India) Ltd manufactures specialized chemicals and is classified as a Micro Cap company. As of March 2025, it reported net sales of 6 Cr and a net profit of 0 Cr, with a market cap of Rs 196 Cr.

Overview: <BR>Arvee Laboratories (India) Ltd is engaged in the manufacturing of specialized chemicals and operates within the Chemicals & Petrochemicals industry, classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated in 2012 as a Private Limited Company and later converted to a Public Limited Company in 2017. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 6 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>- Market Cap: Rs 196 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: 92.00 <BR>- Industry P/E: 47 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -0.16 <BR>- Return on Equity: 6.85% <BR>- Price to Book: 6.27 <BR><BR>Contact Details: <BR>Address: 49/3 B Shyamal Row House, 100 Feet Road Satelitte Ahmedabad Gujarat : 380015 <BR>Tel: 91-79-26749036/37/38 <BR>Email: shalin.patel@arveelabs.com <BR>Website: http://www.arveelabs.com

When is the next results date for Arvee Laborat.?

No Upcoming Board Meetings

What is the bonus history of the Arvee Laborat.?

Arvee Laboratories (India) Ltd issued a 1:1 bonus on October 13, 2020, with a record date of October 14, 2020, allowing shareholders to receive one additional share for each share held.

Arvee Laboratories (India) Ltd has a bonus history that includes a 1:1 bonus issue announced with an ex-date of October 13, 2020. The record date for this bonus was October 14, 2020. This means that shareholders on record as of that date received an additional share for each share they held.

Has Arvee Laborat. declared dividend?

No Dividend History Available

Who are the peers of the Arvee Laborat.?

Peers of Arvee Laborat. include Indian Emuls, Hindcon Chemical, Shri Ahimsa, and others, with similar management risks and growth ratings. All peers, including Arvee Laborat., have a 1-year and six-month return of 0.00%.

Peers: The peers of Arvee Laborat. are Indian Emuls, Hindcon Chemical, Shri Ahimsa, Indian Phosphate, Hi-Green Carbon, Vital Chemtech, Jocil, Paragon Fine, Par Drugs & Che., Mahickra Chem.<BR><BR>Quality Snapshot: Excellent management risk is observed at Indian Emuls, Shri Ahimsa, and Paragon Fine, while Average management risk is found at Hindcon Chemical, Hi-Green Carbon, Vital Chemtech, Jocil, Par Drugs & Che., Mahickra Chem, and Arvee Laborat. Growth is rated as Excellent for Indian Emuls, while Below Average growth is noted for Hindcon Chemical, Shri Ahimsa, Indian Phosphate, Vital Chemtech, Jocil, Paragon Fine, Par Drugs & Che., Mahickra Chem, and Arvee Laborat. Capital Structure is Excellent at Hindcon Chemical, Shri Ahimsa, Jocil, and Par Drugs & Che., while Average is seen at Indian Emuls and Vital Chemtech, and Good at Indian Phosphate, Hi-Green Carbon, Paragon Fine, and Arvee Laborat.<BR><BR>Return Snapshot: All peers, including Arvee Laborat., have a 1-year return of 0.00%, indicating no variation among them. Therefore, there is no peer with a higher or lower return compared to Arvee Laborat. Additionally, all peers have a six-month return of 0.00%, indicating no negative returns.

What is the technical trend for Arvee Laborat.?

As of June 5, 2025, Arvee Laborat's technical trend is neutral with a slight bearish inclination in the short term, driven by mixed MACD signals and mildly bearish daily moving averages.

As of 5 June 2025, the technical trend for Arvee Laborat has changed from mildly bullish to sideways. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands show a mildly bullish stance on the weekly chart but are sideways on the monthly chart. Moving averages on the daily timeframe are mildly bearish, suggesting short-term weakness. The KST and Dow Theory both indicate a mildly bullish outlook on the weekly and monthly charts. Overall, the current technical stance is neutral with a slight bearish inclination in the short term, driven primarily by the daily moving averages and the mixed signals from the MACD.

Who are in the management team of Arvee Laborat.?

As of March 2020, the management team of Arvee Laborat includes Shalin Sudhakarbhai Patel (Chairman & Managing Director), Shalin Bharat Chokshi (Whole-time Director), and seven Independent Directors: Chandrakala Ashok Bhatt, Vishal Nitin Mehta, Amishkumar Maheshkumar Shah, Paragbhai Manubhai Shah, Neetu Jalan, and Sachin Kanwarlal Kansal. Each member contributes to the company's governance and strategic direction.

As of March 2020, the management team of Arvee Laborat consists of the following individuals:<BR><BR>1. Shalin Sudhakarbhai Patel - Chairman & Managing Director<BR>2. Shalin Bharat Chokshi - Whole-time Director<BR>3. Chandrakala Ashok Bhatt - Independent Director<BR>4. Vishal Nitin Mehta - Independent Director<BR>5. Amishkumar Maheshkumar Shah - Independent Director<BR>6. Paragbhai Manubhai Shah - Independent Director<BR>7. Neetu Jalan - Independent Director<BR>8. Sachin Kanwarlal Kansal - Independent Director<BR><BR>Each member plays a significant role in the governance and strategic direction of the company.

How has been the historical performance of Arvee Laborat.?

Arvee Laborat has experienced significant fluctuations in financial performance, with net sales and profits declining from March 2023 to March 2025, despite slight improvements in cash flow. Key metrics such as operating profit and earnings per share also decreased during this period.

Answer:<BR>The historical performance of Arvee Laborat shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Arvee Laborat's net sales have varied considerably, peaking at 62.48 Cr in March 2023 before declining to 38.49 Cr in March 2025. The total operating income followed a similar trend, reaching its highest at 62.48 Cr in March 2023 and dropping to 38.49 Cr in March 2025. The raw material cost has also seen an increase, from 18.87 Cr in March 2025 compared to 16.98 Cr in March 2024, while total expenditure excluding depreciation decreased from 54.07 Cr in March 2023 to 34.87 Cr in March 2025. Operating profit (PBDIT) has fluctuated, with a high of 8.63 Cr in March 2023 and a decrease to 4.28 Cr in March 2025. Profit before tax showed a decline from 6.17 Cr in March 2023 to 2.87 Cr in March 2025, while profit after tax also decreased from 4.12 Cr in March 2023 to 2.15 Cr in March 2025. The earnings per share (EPS) reflected this trend, dropping from 3.74 in March 2023 to 1.95 in March 2025. On the balance sheet, total assets decreased from 38.69 Cr in March 2023 to 38.20 Cr in March 2024, while total liabilities remained relatively stable. Cash flow from operating activities improved slightly from 2.00 Cr in March 2023 to 3.00 Cr in March 2024, with a net cash inflow of 1.00 Cr in March 2024. Overall, the financial performance of Arvee Laborat indicates a challenging period with declining revenues and profits, despite some improvements in cash flow.

Is Arvee Laborat. overvalued or undervalued?

As of November 17, 2025, Arvee Laboratories is considered overvalued and risky, with a PE ratio of 461.66 and an EV to EBITDA of 171.93, significantly higher than its peers, despite a strong historical stock performance.

As of 17 November 2025, the valuation grade for Arvee Laboratories has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios highlight this concern, with a PE ratio of 461.66, an EV to EBITDA of 171.93, and a ROE of just 1.27%. <BR><BR>In comparison to its peers, Arvee's valuation metrics are starkly higher; for instance, Solar Industries has a PE of 95.31 and Gujarat Fluoroch at 57.85, both categorized as very expensive. The high PE ratio and negative EV to EBIT of -178.80 further underscore the risk associated with Arvee's current valuation. Despite a strong performance over the last five years, where the stock returned 303.78% compared to the Sensex's 102.06%, the current valuation suggests that investors should approach with caution.

Are Arvee Laboratories (India) Ltd latest results good or bad?

The latest results for Arvee Laboratories (India) Ltd are concerning, showing a net profit decline of 94.12% quarter-on-quarter and 98.98% year-on-year, with revenue down 53.88% from the previous quarter. These figures indicate serious operational challenges and suggest a fundamental breakdown in the business model, characterizing the results as bad.

The latest results for Arvee Laboratories (India) Ltd are quite concerning. In Q2 FY26, the company reported a net profit of just ₹0.01 crore, which reflects a staggering decline of 94.12% quarter-on-quarter and 98.98% year-on-year. Revenue also took a significant hit, falling to ₹3.45 crores, down 53.88% from the previous quarter and down 72.47% compared to the same quarter last year.<BR><BR>Operating margins have collapsed from 12.05% a year ago to only 3.48% in the latest quarter, indicating severe operational challenges. The profit after tax margin has similarly deteriorated to 0.29%, down from 7.82% in the same period last year. <BR><BR>Overall, these results indicate that the company is facing serious difficulties, with a dramatic decline in both revenue and profitability. The operational metrics suggest a fundamental breakdown in the business model rather than a temporary setback. Given these figures, the latest results can be characterized as bad, raising significant concerns about the company's future viability.

Should I buy, sell or hold Arvee Laboratories (India) Ltd?

Which are the latest news on Arvee Laborat.?

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 17-Mar, Arvee Laboratories (India) Ltd's stock price is at 149.49, down 3.44%, significantly underperforming the Sensex. The stock has declined 29.93% year-to-date and is trading below all moving averages, indicating a bearish trend.

As of 17-Mar, Arvee Laboratories (India) Ltd's stock price is falling, currently at 149.49, which reflects a decrease of 5.32 or 3.44%. The stock has underperformed compared to the benchmark Sensex, which has declined by only 2.80% over the past week. Over the past month, Arvee Laboratories has seen a significant drop of 11.00%, while the Sensex fell by 8.34%. Year-to-date, the stock has decreased by 29.93%, compared to a 9.75% decline in the Sensex.<BR><BR>Additionally, the stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Despite the BSE Small Cap index gaining by 4.12%, Arvee Laboratories has not benefited from this upward movement, further contributing to its decline. Overall, the combination of underperformance against the sector and negative price momentum is driving the stock's price down.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 18-Mar, Arvee Laboratories (India) Ltd's stock price has risen slightly to 150.00, but it remains in a bearish trend with significant declines over the past week, month, and year. The company faces serious challenges, including weak growth and high valuation, leading to a strong sell recommendation despite the recent uptick.

As of 18-Mar, Arvee Laboratories (India) Ltd is experiencing a slight rise in its stock price, currently at 150.00, reflecting a change of 0.51 (0.34%) upwards. However, this positive movement occurs against a backdrop of overall negative performance metrics. Over the past week, the stock has declined by 2.72%, and in the last month, it has fallen by 10.69%. Year-to-date, the stock has decreased by 29.69, significantly underperforming the Sensex, which has only dropped by 9.00%.<BR><BR>Despite the current uptick, the stock is trading below its moving averages across various time frames, indicating a bearish trend. The company also faces significant challenges, including a weak long-term fundamental strength characterized by a -20.49% CAGR growth in operating profits over the last five years and a low return on equity (ROE) of 6.6. Furthermore, the net sales for the latest six months have decreased by 38.29%, and the return on capital employed (ROCE) is at its lowest point of 2.09%.<BR><BR>While the stock has generated a return of 4.90% over the past year, this is overshadowed by a profit decline of 5%. The valuation of the stock is considered expensive, trading at a premium compared to its peers, with a price-to-book value of 5.3. These factors contribute to a perception of the stock as a strong sell, despite the minor rise in price observed today.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 19-Mar, Arvee Laboratories (India) Ltd's stock price has declined to 143.13, down 4.58%, with significant underperformance compared to the Sensex. Weak fundamentals, including a -20.49% CAGR in operating profits and a low ROE of 9.99%, along with disappointing financial results, suggest the stock is overvalued and a strong sell.

As of 19-Mar, Arvee Laboratories (India) Ltd is experiencing a decline in its stock price, currently at 143.13, reflecting a change of -6.87 or -4.58%. This downward movement is evident in the stock's performance over various time frames, with a 1-week decline of -5.46% and a 1-month drop of -15.68%, significantly underperforming the benchmark Sensex, which has decreased by only -2.69% and -9.63% respectively during the same periods.<BR><BR>The company's fundamentals indicate weak long-term growth, with a compound annual growth rate (CAGR) of operating profits at -20.49% over the last five years. Additionally, the return on equity (ROE) stands at a low average of 9.99%, suggesting low profitability relative to shareholders' funds. Recent financial results have also been disappointing, with net sales for the first nine months showing a significant decline of -35.36%. The return on capital employed (ROCE) is at its lowest point of 2.09%, further highlighting the company's struggles.<BR><BR>Moreover, the stock is trading at a premium compared to its peers, with a price-to-book value ratio of 5, indicating an expensive valuation despite the company's poor performance. Over the past year, while the stock has generated a return of -2.52%, profits have decreased by -5%, reinforcing the negative sentiment surrounding the stock. Overall, these factors contribute to the stock's decline, making it a strong sell in the current market environment.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 20-Mar, Arvee Laboratories (India) Ltd's stock price has risen to 146.16, but it has declined significantly over the past month and year-to-date. Despite today's increase, the stock's overall performance and weak fundamentals indicate a troubling long-term outlook.

As of 20-Mar, Arvee Laboratories (India) Ltd's stock price is rising, currently at 146.16, reflecting a change of 3.03 (2.12%) upward. This increase in stock price today is notable as it outperformed the sector by 2.36%. However, it is important to consider the broader context of the stock's performance. Over the past week, the stock has decreased by 1.20%, and in the last month, it has seen a significant decline of 12.67%. Year-to-date, the stock has fallen by 31.49%, indicating a troubling trend.<BR><BR>Despite today's rise, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend overall. Additionally, the company has shown weak long-term fundamental strength, with a -20.49% compound annual growth rate (CAGR) in operating profits over the last five years and a low return on equity (ROE) of 6.6. The latest financial results indicate a significant drop in net sales, which have decreased by 38.29% over the last six months.<BR><BR>In summary, while there is a short-term rise in the stock price today, the overall performance and fundamental indicators suggest a concerning outlook for Arvee Laboratories (India) Ltd, contributing to its long-term decline.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 23-Mar, Arvee Laboratories (India) Ltd's stock price is Rs 141.25, down 3.36%, with a year-to-date decline of 33.79%. The stock is trading below all moving averages and is near its 52-week low, indicating a bearish trend.

As of 23-Mar, Arvee Laboratories (India) Ltd's stock price is falling, currently at Rs 141.25, which reflects a decrease of Rs 4.91 or 3.36%. The stock has shown a significant decline over various periods, with a year-to-date drop of 33.79%, which is notably worse than the benchmark Sensex's decline of 13.84% during the same timeframe. Over the past week, the stock has decreased by 8.76%, while the Sensex fell by 3.83%. <BR><BR>Additionally, the stock is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. It is also close to its 52-week low, being only 4.67% away from Rs 134.65. Despite outperforming its sector by 0.38% today, the overall performance metrics suggest a downward trajectory for the stock.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 24-Mar, Arvee Laboratories (India) Ltd's stock price is Rs 138.00, down 2.3%, reflecting a significant decline of 35.31% year-to-date, underperforming the Sensex. The company faces weak fundamentals, including a 38.29% drop in net sales and a low return on capital employed, contributing to a perception of being overvalued.

As of 24-Mar, Arvee Laboratories (India) Ltd is experiencing a decline in its stock price, currently at Rs 138.00, which reflects a decrease of Rs 3.25 or 2.3%. This downward movement is supported by several factors highlighted in the recent performance data. Over the past week, the stock has dropped by 7.69%, significantly underperforming the benchmark Sensex, which fell only 2.84%. <BR><BR>In the last month, the stock has decreased by 10.97%, while the Sensex has seen a smaller decline of 9.88%. Year-to-date, Arvee Laboratories has faced a substantial drop of 35.31%, compared to the Sensex's 12.31% decline. Additionally, the stock is trading close to its 52-week low, just 2.43% above Rs 134.65, indicating a weak market position.<BR><BR>The company's performance metrics further illustrate its struggles. It has underperformed its sector by 4.69% today and is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Financially, Arvee Laboratories has shown weak long-term fundamentals, with a -20.49% compound annual growth rate (CAGR) in operating profits over the last five years and a low return on equity (ROE) of 6.6%. <BR><BR>Moreover, the company's net sales for the latest six months have plummeted by 38.29%, and its return on capital employed (ROCE) is at a concerning low of 2.09%. These factors contribute to a perception of the stock being overvalued, trading at a premium compared to its peers, which further discourages investment. Overall, the combination of poor financial performance, significant declines in stock value, and unfavorable comparisons to benchmarks and sector performance are driving the stock's decline.

Why is Arvee Laboratories (India) Ltd falling/rising?

As of 25-Mar, Arvee Laboratories (India) Ltd's stock price has risen to Rs 141.24, up 2.35%, despite weak overall performance and a year-to-date decline of 33.79%. The company's concerning fundamentals indicate that this short-term price increase may not be sustainable.

As of 25-Mar, Arvee Laboratories (India) Ltd is experiencing a rise in its stock price, currently at Rs 141.24, reflecting an increase of Rs 3.24 or 2.35%. This upward movement is notable despite the company's overall weak performance metrics. The stock has outperformed its sector by 0.65% today, which may contribute to the positive sentiment around its price increase.<BR><BR>However, it is important to consider the broader context of the stock's performance. Over the past week, the stock has declined by 5.84%, and it is currently trading 4.67% above its 52-week low of Rs 134.65. Additionally, the stock has shown a significant year-to-date decline of 33.79%, indicating ongoing challenges.<BR><BR>The company's fundamentals are concerning, with a negative compound annual growth rate (CAGR) of -20.49% in operating profits over the last five years and a return on equity (ROE) of only 6.6%. These factors suggest that while there may be short-term price movements, the long-term outlook remains weak, as evidenced by a 4.9 price-to-book value ratio that indicates an expensive valuation compared to peers.<BR><BR>In summary, while the stock is rising today, the underlying financial health of Arvee Laboratories suggests that this may not be sustainable in the long term, as the company faces significant operational challenges and a declining trend in profitability.